JP2012500778A - アンドロゲン受容体のｎ末端の活性化の小分子阻害剤 - Google Patents

アンドロゲン受容体のｎ末端の活性化の小分子阻害剤 Download PDF

Info

Publication number
JP2012500778A
JP2012500778A JP2011523280A JP2011523280A JP2012500778A JP 2012500778 A JP2012500778 A JP 2012500778A JP 2011523280 A JP2011523280 A JP 2011523280A JP 2011523280 A JP2011523280 A JP 2011523280A JP 2012500778 A JP2012500778 A JP 2012500778A
Authority
JP
Japan
Prior art keywords
saturated
branched
compound
formula
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2011523280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500778A5 (enExample
Inventor
ディー． サダル、マリアン
アール． マウジ、ナスリン
ワン、ジュン
ジェイ． アンダーソン、レイモンド
イー． ウィリアムズ、デイヴィッド
ルブラン、マイク
ヤン、ルー−ピン
Original Assignee
ブリティッシュ コロンビア キャンサー エージェンシー ブランチ
ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41706796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012500778(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ブリティッシュ コロンビア キャンサー エージェンシー ブランチ, ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア filed Critical ブリティッシュ コロンビア キャンサー エージェンシー ブランチ
Publication of JP2012500778A publication Critical patent/JP2012500778A/ja
Publication of JP2012500778A5 publication Critical patent/JP2012500778A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011523280A 2008-08-22 2009-08-24 アンドロゲン受容体のｎ末端の活性化の小分子阻害剤 Abandoned JP2012500778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13627708P 2008-08-22 2008-08-22
US61/136,277 2008-08-22
PCT/CA2009/001173 WO2010020055A1 (en) 2008-08-22 2009-08-24 Small molecule inhibitors of n-terminus activation of the androgen receptor

Publications (2)

Publication Number Publication Date
JP2012500778A true JP2012500778A (ja) 2012-01-12
JP2012500778A5 JP2012500778A5 (enExample) 2012-10-11

Family

ID=41706796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523280A Abandoned JP2012500778A (ja) 2008-08-22 2009-08-24 アンドロゲン受容体のｎ末端の活性化の小分子阻害剤

Country Status (13)

Country Link
US (2) US9487479B2 (enExample)
EP (1) EP2331501B1 (enExample)
JP (1) JP2012500778A (enExample)
CN (1) CN102131775B (enExample)
AU (1) AU2009284668B2 (enExample)
BR (1) BRPI0917818A2 (enExample)
CA (1) CA2728103C (enExample)
CL (1) CL2011000341A1 (enExample)
CO (1) CO6351779A2 (enExample)
ES (1) ES2593859T3 (enExample)
MX (1) MX339300B (enExample)
RU (1) RU2519948C2 (enExample)
WO (1) WO2010020055A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0917818A2 (pt) 2008-08-22 2017-02-21 British Columbia Cancer Agency Branch composto, método para modular a atividade de ar, uso de composto, composição farmacêutica, e, para preparar um composto
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10799416B2 (en) * 2017-01-11 2020-10-13 Jonathan Taves Self-treating upper neck system for therapeutic mobilization
CN107468690B (zh) * 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh) 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
RU2700573C2 (ru) * 2017-10-16 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2694259C2 (ru) * 2017-10-16 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2694373C2 (ru) * 2017-10-16 2019-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2696287C2 (ru) * 2017-10-16 2019-08-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0317057A (ja) * 1989-06-15 1991-01-25 Fujisawa Pharmaceut Co Ltd 新規５員環複素環化合物
WO2000001813A2 (en) 1998-06-30 2000-01-13 The University Of British Columbia Peptide inhibitors of androgen-independent activation of androgen receptor
WO2001095858A2 (en) * 2000-05-09 2001-12-20 Adpharma, Inc. Piperazinedione compounds
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
BRPI0917818A2 (pt) 2008-08-22 2017-02-21 British Columbia Cancer Agency Branch composto, método para modular a atividade de ar, uso de composto, composição farmacêutica, e, para preparar um composto
AU2015266654A1 (en) 2014-05-30 2016-12-01 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
JP2020143126A (ja) * 2014-05-30 2020-09-10 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法

Also Published As

Publication number Publication date
US20170239216A1 (en) 2017-08-24
CO6351779A2 (es) 2011-12-20
CA2728103C (en) 2017-06-27
RU2519948C2 (ru) 2014-06-20
US9487479B2 (en) 2016-11-08
ES2593859T3 (es) 2016-12-13
RU2011110743A (ru) 2012-09-27
CA2728103A1 (en) 2010-02-25
AU2009284668B2 (en) 2015-07-09
MX339300B (es) 2016-05-19
CN102131775A (zh) 2011-07-20
WO2010020055A1 (en) 2010-02-25
CN102131775B (zh) 2015-12-16
US20110230539A1 (en) 2011-09-22
EP2331501B1 (en) 2016-07-20
MX2011001890A (es) 2011-06-20
EP2331501A4 (en) 2012-06-06
HK1153198A1 (zh) 2012-03-23
AU2009284668A1 (en) 2010-02-25
CL2011000341A1 (es) 2011-09-02
BRPI0917818A2 (pt) 2017-02-21
EP2331501A1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
JP6190025B2 (ja) ジグリシドエーテル誘導体治療剤およびその使用方法
EP2331501B1 (en) Small molecule inhibitors of n-terminus activation of the androgen receptor
JP5940982B2 (ja) アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用
CN111527100A (zh) 肽类抗生素
HK1153198B (en) Small molecule inhibitors of n-terminus activation of the androgen receptor
HK1150593B (en) Diglycidic ether derivative therapeutics and methods for their use
HK1150593A (en) Diglycidic ether derivative therapeutics and methods for their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120824

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20131212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131212